SM19712
Based on 1 Customer Validation
SM19712 is an orally active, selective endothelin converting enzyme (ECE) inhibitor. SM19712 inhibits conversion of big ET-1 to ET-1. SM19712 attenuates colonic angiogenesis, tissue injury, inflammation, without altering colon shortening or myeloperoxidase levels in mice. SM19712 can be used for the research of inflammatory bowel disease (colitis), ischemic acute renal failure, acute myocardial infarction, and myocardial ischemia/reperfusion injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.0%
- CAS No.: 194542-56-8
- Formule: C18H13ClN5NaO3S
- Masse moléculaire:437.84
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
IC50 & Target
[1]|
ECE-1 |
In Vitro
SM19712 potently inhibits ECE solubilized from rat lung microsomes with an IC50 of 42 nM[3].
SM19712 (10-300 μM) shows high specificity for ECE, with no significant inhibitory activity against NEP, ACE, 13 tested receptors, or 9 tested enzymes at concentrations up to 300 μM[3].
SM19712 (1-100 μM; 6 h) concentration-dependently inhibits endogenous ET-1 production in cultured porcine aortic endothelial cells with an IC50 of 31 μM[3].
SM19712 (100 μM) exhibits high selectivity for endothelin-converting enzyme, with minimal inhibitory effects on neutral endopeptidase, angiotensin converting enzyme, collagenase IV, and other proteinase classes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
SM19712 (3-30 mg/kg; i.v.; single bolus 5 minutes before occlusion) dose-dependently attenuates ischemia/reperfusion-induced acute renal failure in Sprague-Dawley rats[2].
SM19712 (0.3-30 mg/kg; i.v.; single dose) dose-dependently suppresses Big ET-1-induced pressor responses in rats[3].
SM19712 (10-30 mg/kg; p.o.; single dose) significantly suppresses big ET-1-induced pressor responses in rats by 37.2%[3].
SM19712 (25.9 mg/kg bolus, 1.7 mg/kg/min infusion; i.v.; single bolus followed by continuous infusion; duration of experiment) significantly reduces infarct size, serum ET-1 elevation, and serum CPK activity in a rabbit model of acute myocardial infarction induced by coronary occlusion and reperfusion[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (~28 g; inflammatory bowel disease induced by 5% 40 kD Dextran Sodium Sulfate (DDS) in drinking water for 5-6 days)[1]
-
Dosage:15 mg/kg/day
-
Administration:p.o.; daily; 5-6 days
-
Result:Attenuated DSS-induced increases in colonic ET-1 immunostaining.
Reduced DSS-induced PECAM-1 immunostaining.
Attenuated DSS-induced histologic injury and inflammation.
Decreased the incidence of loose stools and fecal blood.
Reduced DSS-induced weight loss.
Significantly decreased the overall disease activity index in DSS-treated mice.
Did not significantly affect DSS-induced colon shortening or tissue myeloperoxidase activity.
-
Animal Model:Sprague-Dawley rats (male, 10 weeks old, 280-300 g, acute renal failure induced by right nephrectomy 2 weeks prior followed by 45-minute left renal artery and vein occlusion then reperfusion)[2]
-
Dosage:3; 10; 30 mg/kg
-
Administration:i.v.; single bolus 5 minutes before occlusion
-
Result:Reduced BUN, increased creatinine clearance, reduced urine flow, increased urinary osmolality, and reduced fractional excretion of sodium.
Attenuated tubular necrosis grade, proteinaceous casts grade, and medullary congestion grade.
Reduced renal ET-1 content.
-
Animal Model:Sprague-Dawley rats (male, 300-400 g, anesthetized, ganglionic-blocked, challenged with Big Edothelin-1)[3]
-
Dosage:0.3; 1; 3; 10; 30 mg/kg
-
Administration:i.v.; single dose
-
Result:Dose-dependently suppressed the pressor response induced by Big ET-1.
Significantly reduced the pressor response.
Had no effect on baseline pressure or the pressor response induced by mature ET-1.
-
Animal Model:Sprague-Dawley rats (male, 280-400 g, conscious then anesthetized, challenged with big endothelin-1)[3]
-
Dosage:10; 30 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced a 37.2% suppression of the big ET-1-induced pressor response at 30 mg/kg.
-
Animal Model:New Zealand White rabbits (male, 2.6-3.5 kg, subjected to 30 minutes of coronary artery occlusion followed by 5 hours of reperfusion)[3]
-
Dosage:25.9 mg/kg (bolus); 1.7 mg/kg/min (continuous infusion)
-
Administration:i.v.; single bolus followed by continuous infusion; duration of experiment
-
Result:Significantly reduced myocardial infarct size, expressed as a percentage of both the left ventricle area and the area at risk, compared to vehicle.
Significantly attenuated the increase in serum ET-1 concentration and serum CPK activity seen in vehicle-treated rabbits during reperfusion.
Chemical Information
-
CAS No. 194542-56-8
-
Appearance Solid
-
Masse moléculaire 437.84
-
Formule C18H13ClN5NaO3S
-
Color White to off-white
-
SMILES
O=C(N([Na])S(=O)(C1=CC=C(Cl)C=C1)=O)NC2=C(C#N)C(C)=NN2C3=CC=CC=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocole
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lee S, et al. Effects of the endothelin-converting enzyme inhibitor SM-19712 in a mouse model of dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2009 Jul;15(7):1007-13. [Content Brief]
[2]. Matsumura Y, et al. Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jpn J Pharmacol. 2000 Sep;84(1):16-24. [Content Brief]
[3]. Umekawa K, et al. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol. 2000 Sep;84(1):7-15. [Content Brief]
[4]. Tawa M, et al. Role of endogenous endothelin-1 in post-ischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Eur J Pharmacol. 2008 Sep 4;591(1-3):182-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- SM19712
- 194542-56-8
- SM 19712
- SM-19712
- Endothelin-Converting Enzyme (ECE)
- Endothelin Receptor
- endothelin converting enzyme
- ischemic acute renal failure
- rat lung microsomes
- inflammatory bowel disease
- acute myocardial infarction
- human middle meningeal arteries
- Sprague-Dawley rats
- porcine aortic endothelial cells
- human coronary arteries
- C57BL/6 mice
- Inhibitor
- inhibitor
- inhibit